Genomic predictors of treatment response in prostate cancer
4 Jul 2017
Genomic predictors of treatment response in prostate cancer
Synthetic lethality as a basis to select drug combinations
Genomic analysis of childhood tumours; biological and therapeutic implications
Patient-specific peptide vaccines
Proteogenomics in cancer research
Novel models to personalise cancer therapeutics
The Umberto Veronesi Milan Breast Cancer Conference
Latest maintenance strategies in multiple myeloma
Lenalidomide with CD19 antibodies in L-MIND
Denosumab or zoledronic acid for bone disease in multiple myeloma
Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM
Impact of mutational profile at diagnosis for MDS/CML